Blinatumomab is a bispecific T-cell engager antibody simultaneously binding CTLs and CD19-positive BCP-ALL cells [24], suggesting that TRAIL/death receptor system may also be involved in anti-leukemic activities of blinatumomab. The gene discussed is TNFSF10; the disease is acute lymphoblastic leukemia.